Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 12Gliosarcoma 9Central Nervous System Neoplasms 6Astrocytoma 6Brain Neoplasms 5Oligodendroglioma 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma, Subependymal 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sinonasal Squamous Cell Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pinealoma 1Pheochromocytoma 1Peritoneal Neoplasms 1Pancreatic Intraductal Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Mesothelioma 1Meningioma 1Melanoma 1

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sinonasal Squamous Cell Carcinoma × Surgical Procedures, Operative × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡